NCCN
Outcomes4Me Incorporates NCCN Hereditary Cancer Risk Testing Guidelines Into Patient-Facing App
The integration, Outcomes4Me hopes, will help address healthcare disparities by improving access to information about cancer risk testing.
A recent JAMA study underscores racial disparities in genetic test access, which UPenn's Basser Center aims to address through its Black &Â BRCAÂ initiative.
Puma Biotechnology Provides $1.4M to NCCN-Chosen Studies of Nerlynx in Gastric Cancers
The grants will fund combination studies of neratinib in HER2-expressing gastroesophageal cancers and advanced refractory gastric cancer.
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
NCCN Publishes First Set of Guidelines for Wilms Tumor
In addition to treatment regimens, the guidelines include recommendations for molecular testing and surveillance for patients with predisposition syndromes.